A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Cellulite
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 24 Jul 2018 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.
- 24 Jul 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.